West Net Debt vs Retained Earnings Analysis

WST Stock

USD 331.40 0.00 0.00%

West Pharmaceutical financial indicator trend analysis is more than just analyzing West Pharmaceutical current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether West Pharmaceutical is a good investment. Please check the relationship between West Pharmaceutical Net Debt and its Retained Earnings accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Net Debt vs Retained Earnings

Net Debt vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of West Pharmaceutical Net Debt account and Retained Earnings. At this time, the significance of the direction appears to have pay attention.

The correlation between West Pharmaceutical's Net Debt and Retained Earnings is -0.93. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of West Pharmaceutical Services, assuming nothing else is changed. The correlation between historical values of West Pharmaceutical's Net Debt and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of West Pharmaceutical Services are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Net Debt i.e., West Pharmaceutical's Net Debt and Retained Earnings go up and down completely randomly.

Correlation Coefficient

-0.93

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most indicators from West Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into West Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

At this time, West Pharmaceutical's Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 31.87 in 2024, whereas Enterprise Value is likely to drop slightly above 252.4 M in 2024.

	2021	2022	2023	2024 (projected)
Total Revenue	2.8B	2.9B	2.9B	3.1B
Depreciation And Amortization	122.3M	120.6M	137.3M	144.2M

Total Revenue Depreciation And Amortization

West Pharmaceutical fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Property Plant And Equipment Gross	Common Stock Total Equity	Common Stock
Total Assets		0.32	0.86	0.98	0.98	0.98	-0.87	0.97	0.97	0.98	0.48	0.97	0.98	0.67	0.12	0.99	0.91	-0.7	0.76	0.99	0.65	-0.35	0.98	0.94	0.54	0.54
Short Long Term Debt Total	0.32		0.12	0.29	0.16	0.3	0.12	0.11	0.16	0.4	0.2	0.17	0.22	0.56	0.92	0.26	0.21	0.09	0.58	0.21	0.07	0.72	0.3	0.11	0.35	0.35
Other Current Liab	0.86	0.12		0.87	0.87	0.82	-0.85	0.84	0.9	0.83	0.56	0.9	0.88	0.61	0.01	0.87	0.77	-0.5	0.59	0.89	0.38	-0.4	0.89	0.79	0.58	0.58
Total Current Liabilities	0.98	0.29	0.87		0.96	0.96	-0.86	0.96	0.95	0.96	0.5	0.95	0.96	0.65	0.08	0.98	0.92	-0.72	0.76	0.97	0.7	-0.33	0.98	0.93	0.49	0.5
Total Stockholder Equity	0.98	0.16	0.87	0.96		0.97	-0.93	0.99	0.98	0.96	0.44	0.98	0.99	0.63	-0.04	0.99	0.91	-0.72	0.66	0.99	0.65	-0.5	0.97	0.96	0.54	0.55
Property Plant And Equipment Net	0.98	0.3	0.82	0.96	0.97		-0.83	0.97	0.93	0.99	0.32	0.93	0.96	0.71	0.1	0.98	0.91	-0.71	0.68	0.96	0.71	-0.35	0.96	0.93	0.58	0.58
Net Debt	-0.87	0.12	-0.85	-0.86	-0.93	-0.83		-0.93	-0.95	-0.79	-0.48	-0.95	-0.92	-0.44	0.32	-0.9	-0.79	0.69	-0.5	-0.93	-0.54	0.71	-0.87	-0.89	-0.47	-0.48
Retained Earnings	0.97	0.11	0.84	0.96	0.99	0.97	-0.93		0.97	0.94	0.39	0.97	0.97	0.56	-0.09	0.98	0.93	-0.81	0.66	0.98	0.71	-0.51	0.94	0.98	0.46	0.47
Cash	0.97	0.16	0.9	0.95	0.98	0.93	-0.95	0.97		0.92	0.53	1.0	0.98	0.57	-0.03	0.98	0.88	-0.71	0.71	0.99	0.57	-0.48	0.96	0.94	0.51	0.52
Non Current Assets Total	0.98	0.4	0.83	0.96	0.96	0.99	-0.79	0.94	0.92		0.38	0.92	0.95	0.76	0.22	0.97	0.9	-0.64	0.74	0.95	0.65	-0.25	0.97	0.9	0.59	0.6
Non Currrent Assets Other	0.48	0.2	0.56	0.5	0.44	0.32	-0.48	0.39	0.53	0.38		0.53	0.52	0.29	0.15	0.48	0.43	-0.11	0.54	0.52	0.06	-0.1	0.51	0.43	0.12	0.13
Cash And Short Term Investments	0.97	0.17	0.9	0.95	0.98	0.93	-0.95	0.97	1.0	0.92	0.53		0.98	0.56	-0.02	0.98	0.88	-0.71	0.71	0.99	0.57	-0.47	0.96	0.94	0.51	0.51
Net Receivables	0.98	0.22	0.88	0.96	0.99	0.96	-0.92	0.97	0.98	0.95	0.52	0.98		0.67	0.03	0.99	0.9	-0.66	0.71	0.99	0.59	-0.45	0.98	0.93	0.55	0.56
Common Stock Shares Outstanding	0.67	0.56	0.61	0.65	0.63	0.71	-0.44	0.56	0.57	0.76	0.29	0.56	0.67		0.43	0.67	0.57	-0.06	0.42	0.62	0.3	0.02	0.72	0.48	0.75	0.76
Non Current Liabilities Total	0.12	0.92	0.01	0.08	-0.04	0.1	0.32	-0.09	-0.03	0.22	0.15	-0.02	0.03	0.43		0.07	0.03	0.26	0.48	0.02	-0.21	0.84	0.1	-0.09	0.17	0.16
Inventory	0.99	0.26	0.87	0.98	0.99	0.98	-0.9	0.98	0.98	0.97	0.48	0.98	0.99	0.67	0.07		0.91	-0.7	0.72	0.99	0.64	-0.4	0.98	0.95	0.55	0.55
Other Current Assets	0.91	0.21	0.77	0.92	0.91	0.91	-0.79	0.93	0.88	0.9	0.43	0.88	0.9	0.57	0.03	0.91		-0.81	0.73	0.91	0.73	-0.34	0.87	0.95	0.32	0.33
Other Stockholder Equity	-0.7	0.09	-0.5	-0.72	-0.72	-0.71	0.69	-0.81	-0.71	-0.64	-0.11	-0.71	-0.66	-0.06	0.26	-0.7	-0.81		-0.57	-0.71	-0.78	0.45	-0.62	-0.85	0.02	0.01
Total Liab	0.76	0.58	0.59	0.76	0.66	0.68	-0.5	0.66	0.71	0.74	0.54	0.71	0.71	0.42	0.48	0.72	0.73	-0.57		0.73	0.38	0.13	0.72	0.67	0.15	0.16
Total Current Assets	0.99	0.21	0.89	0.97	0.99	0.96	-0.93	0.98	0.99	0.95	0.52	0.99	0.99	0.62	0.02	0.99	0.91	-0.71	0.73		0.61	-0.44	0.97	0.95	0.52	0.53
Short Term Debt	0.65	0.07	0.38	0.7	0.65	0.71	-0.54	0.71	0.57	0.65	0.06	0.57	0.59	0.3	-0.21	0.64	0.73	-0.78	0.38	0.61		-0.33	0.61	0.74	0.14	0.15
Intangible Assets	-0.35	0.72	-0.4	-0.33	-0.5	-0.35	0.71	-0.51	-0.48	-0.25	-0.1	-0.47	-0.45	0.02	0.84	-0.4	-0.34	0.45	0.13	-0.44	-0.33		-0.37	-0.49	-0.16	-0.16
Accounts Payable	0.98	0.3	0.89	0.98	0.97	0.96	-0.87	0.94	0.96	0.97	0.51	0.96	0.98	0.72	0.1	0.98	0.87	-0.62	0.72	0.97	0.61	-0.37		0.9	0.59	0.6
Property Plant And Equipment Gross	0.94	0.11	0.79	0.93	0.96	0.93	-0.89	0.98	0.94	0.9	0.43	0.94	0.93	0.48	-0.09	0.95	0.95	-0.85	0.67	0.95	0.74	-0.49	0.9		0.37	0.38
Common Stock Total Equity	0.54	0.35	0.58	0.49	0.54	0.58	-0.47	0.46	0.51	0.59	0.12	0.51	0.55	0.75	0.17	0.55	0.32	0.02	0.15	0.52	0.14	-0.16	0.59	0.37		1.0
Common Stock	0.54	0.35	0.58	0.5	0.55	0.58	-0.48	0.47	0.52	0.6	0.13	0.51	0.56	0.76	0.16	0.55	0.33	0.01	0.16	0.53	0.15	-0.16	0.6	0.38	1.0

Click cells to compare fundamentals

West Pharmaceutical Account Relationship Matchups

West Pharmaceutical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.3B	2.8B	3.3B	3.6B	3.8B	4.0B
Short Long Term Debt Total	329.3M	325.7M	325.3M	317.9M	309M	230.5M
Other Current Liab	145.4M	175.4M	211.1M	173.6M	187.3M	196.7M
Total Current Liabilities	341.6M	503.4M	594.1M	519M	671.8M	705.4M
Total Stockholder Equity	1.6B	1.9B	2.3B	2.7B	2.9B	3.0B
Property Plant And Equipment Net	909.4M	1.0B	1.1B	1.3B	1.5B	1.6B
Net Debt	(109.8M)	(289.8M)	(437.3M)	(576.4M)	(544.9M)	(517.7M)
Retained Earnings	1.5B	1.8B	2.5B	3.0B	3.5B	3.7B
Cash	439.1M	615.5M	762.6M	894.3M	853.9M	896.6M
Non Current Assets Total	1.3B	1.4B	1.6B	1.7B	1.9B	2.0B
Non Currrent Assets Other	20.5M	29M	36.3M	55.9M	38.4M	32.0M
Cash And Short Term Investments	439.1M	615.5M	762.6M	894.3M	853.9M	896.6M
Net Receivables	319.3M	385.3M	489M	507.4M	512M	537.6M
Liabilities And Stockholders Equity	2.3B	2.8B	3.3B	3.6B	3.8B	4.0B
Non Current Liabilities Total	426.6M	435.9M	384.3M	412.9M	276.7M	307.8M
Inventory	235.7M	321.3M	378.4M	414.8M	434.7M	456.4M
Other Current Assets	64.6M	51.6M	112M	103M	135.8M	142.6M
Other Stockholder Equity	154.6M	99.6M	19.5M	(138.7M)	(517.4M)	(491.5M)
Total Liab	768.2M	939.3M	978.4M	931.9M	948.5M	995.9M
Total Current Assets	1.1B	1.4B	1.7B	1.9B	1.9B	2.0B
Short Term Debt	11.9M	22.5M	62.8M	34.2M	169.4M	177.9M
Intangible Assets	29.8M	30.5M	23M	18.4M	15.1M	14.3M
Accounts Payable	156.8M	213.1M	232.2M	215.4M	242.4M	254.5M
Property Plant And Equipment Gross	909.4M	1.0B	2.2B	2.4B	2.8B	3.0B
Accumulated Other Comprehensive Income	(149.6M)	(110.6M)	(159.6M)	(183M)	(143.8M)	(151.0M)
Other Liab	109.2M	117M	112.5M	113.2M	130.2M	107.9M
Other Assets	43M	52.3M	104.4M	104M	93.6M	47.0M
Long Term Debt	255M	252.9M	208.8M	206.7M	72.8M	69.2M
Good Will	107.8M	111.1M	109.9M	107.3M	108.5M	103.1M
Treasury Stock	(118.1M)	(167.7M)	(229.5M)	(370.9M)	(333.8M)	(317.1M)
Property Plant Equipment	839.3M	943.2M	1.1B	1.2B	1.3B	1.4B
Current Deferred Revenue	27.5M	51M	48.7M	57.3M	41.7M	38.2M
Net Tangible Assets	1.4B	1.7B	2.1B	2.6B	2.9B	3.1B
Retained Earnings Total Equity	1.5B	1.8B	2.5B	3.0B	3.4B	3.6B
Long Term Debt Total	255M	252.9M	208.8M	206.7M	186.0M	209.4M
Capital Surpluse	272.7M	267.3M	249M	232.2M	267.0M	223.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for West Stock Analysis

When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC